Pathogenesis of renal disease in Systemic Lupus Erythematosus—the role of autoantibodies and lymphocytes subset abnormalities

International Journal of Molecular Sciences

Volumn 16, Issue 4, 2015, Pages 7917-7931

  Yap, Desmond Y H ^a   Lai, Kar N ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Autoantibodies; Lupus nephritis; Lymphocytes; Pathogenesis; Subsets

Indexed keywords

ALPHA ACTININ; AUTOANTIBODY; B CELL ACTIVATING FACTOR; COMPLEMENT COMPONENT C1Q ANTIBODY; CXCL13 CHEMOKINE; DOUBLE STRANDED DNA ANTIBODY; NUCLEOSOME AUTOANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

ANTIGEN BINDING; ANTIGEN PRESENTATION; DISEASE ACTIVITY; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HELPER CELL; HUMAN; IMMUNE RESPONSE; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; MEMORY CELL; PATHOGENESIS; PLEIOTROPY; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL; B LYMPHOCYTE; IMMUNOLOGY; PATHOLOGY;

AUTOANTIBODIES; B-LYMPHOCYTES; HUMANS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84927586388     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16047917     Document Type: Review

References (90)

1. Danchenko, N.; Satia, J.A.; Anthony, M.S. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus 2006, 15, 308-318.
2. Osio-Salido, E.; Manapat-Reyes, H. Epidemiology of systemic lupus erythematosus in Asia. Lupus 2010, 19, 1365-1373.
3. Korbet, S.M.; Schwartz, M.M.; Evans, J.; Lewis, E.J. Severe lupus nephritis: Racial differences in presentation and outcome. J. Am. Soc. Nephrol. 2007, 18, 244-254.
4. Rovin, B.H.; Zhang, X. Biomarkers for lupus nephritis: The quest continues. Clin. J. Am. Soc. Nephrol. 2009, 4, 1858-1865.
5. Winfield, J.B.; Faiferman, I.; Koffler, D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J. Clin. Investig. 1977, 59, 90-96.
6. Kalunian, K.C.; Panosian-Sahakian, N.; Ebling, F.M.; Cohen, A.H.; Louie, J.S.; Kaine, J.; Hahn, B.H. Idiotypic characteristics of immunoglobulins associated with systemic lupus erythematosus. Studies of antibodies deposited in glomeruli of humans. Arthritis Rheumatol. 1989, 32, 513-522.
7. Termaat, R.M.; Assmann, K.J.; van Son, J.P.; Dijkman, H.B.; Koene, R.A.; Berden, J.H. Antigen-specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus-like syndromes. Lab. Investig. 1993, 68, 164-173.
8. Vlahakos, D.V.; Foster, M.H.; Adams S.; Katz, M.; Ucci, A.A.; Barrett, K.J.; Datta, S.K.; Madaio, M.P. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int. 1992, 41, 1690-1700.
9. Yung, S.; Cheung, K.F.; Zhang, Q.; Chan, T.M. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J. Am. Soc. Nephrol. 2010, 21, 1912-1927.
10. Fenton, K.A.; Tommeras, B.; Marion, T.N.; Rekvig, O.P. Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity 2010, 43, 179-188.
11. Chan, T.M.; Leung, J.K.; Ho, S.K.; Yung, S. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 2002, 13, 1219-1229.
12. Croquefer, S.; Renaudineau, Y.; Jousse, S.; Gueguen, P.; Ansart, S.; Saraux, A.; Youinou, P. The ananti-α-actinin test completes ananti-DNA determination in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 2005, 1050, 170-175.
13. Zhao, Z.; Weinstein, E.; Tuzova, M.; Davidson, A.; Mundel, P.; Marambio, P.; Putterman, C. Cross-reactivity of human lupus anti-DNA antibodies with α-actinin and nephritogenic potential. Arthritis Rheumatol. 2005, 52, 522-530.
14. Zhao, Z.; Deocharan, B.; Scherer, P.E.; Ozelius, L.J.; Putterman, C. Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: The role of α-actinin. J. Immunol. 2006, 176, 7704-7714.
15. Mortensen, E.S.; Rekvig, O.P. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J. Am. Soc. Nephrol. 2009, 20, 696-704.
16. Mjelle, J.E.; Rekvig, O.P.; van der Vlag, J.; Fenton, K.A. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 2011, 44, 373-383.
17. Hedberg, A.; Fismen, S.; Fenton, K.A.; Fenton, C.; Osterud, B.; Mortensen, E.S.; Rekvig, O.P. Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheumatol. 2011, 63, 1065-1075.
18. Yung, S.; Tsang, R.C.; Sun, Y.; Leung, J.K.; Chan, T.M. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: Implications on tubulointerstitial inflammation in lupus nephritis. J. Am. Soc. Nephrol. 2005, 16, 3281-3294.
19. Koren, E.; Koscec, M.; Wolfson-Reichlin, M.; Ebling, F.M.; Tsao, B.; Hahn, B.H.; Reichlin, M. Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. J. Immunol. 1995, 154, 4857-4864.
20. Zack, D.J.; Stempniak, M.; Wong, A.L.; Taylor, C.; Weisbart, R.H. Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J. Immunol. 1996, 157, 2082-2088.
21. Chan, T.M.; Frampton, G.; Jayne, D.R.; Perry, G.J.; Lockwood, C.M.; Cameron, J.S. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: A longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am. J. Kidney Dis. 1993, 22, 387-392.
22. Chan, T.M.; Cheng, I.K. A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1996, 78, 41-46.
23. Chan, T.M.; Frampton, G.; Cameron, J.S. Identification of DNA-binding proteins on human umbilical vein endothelial cell plasma membrane. Clin. Exp. Immunol. 1993, 91, 110-114.
24. Chan, T.M.; Frampton, G.; Staines, N.A.; Hobby, P.; Perry, G.J.; Cameron, J.S. Different mechanisms by which anti-DNA MoAbs bind to human endothelial cells and glomerular mesangial cells. Clin. Exp. Immunol. 1992, 88, 68-74.
25. Lai, K.N.; Leung, J.C.; Lai, B.K.; Li, P.K.; Lai, C.K. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J. Pathol. 1996, 178, 451-457.
26. Lai, K.N.; Leung, J.C.; Lai, K.B.; Lai, F.M.; Wong, K.C. Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies. Ann. Rheum. Dis. 1996, 55, 57-62.
27. Lai, K.N.; Leung, J.C.; Lai, K.B.; Lai, C.K. Effect of anti-DNA autoantibodies on the gene expression of interleukin 8, transforming growth factor-β, and nitric oxide synthase in cultured endothelial cells. Scand. J. Rheumatol. 1997, 26, 461-467.
28. Krishnan, M.R.; Wang, C.; Marion, T.N. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int. 2012, 82, 184-192.
29. Heinz, H.P.; Rubin, K.; Laurell, A.B.; Loos, M. Common epitopes in Clq and collagen type II. Mol. Immunol. 1989, 26, 163-169.
30. Wener, M.H.; Mannik, M.; Schwartz, M.M.; Lewis, E.J. Relationship between renal pathology and the size of circulating immune complexes in patients with systemic lupus erythematosus. Medicine (Baltimore) 1987, 66, 85-97.
31. Uwatoko, S.; Mannik, M. Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. J. Clin. Investig. 1988, 82, 816-824.
32. Pang, Y.; Yang, X.W.; Song, Y.; Yu, F.; Zhao, M.H. Anti-C1q autoantibodies from active lupus nephritis patients could inhibit the clearance of apoptotic cells and complement classical pathway activation mediated by C1q in vitro. Immunobiology 2014, 219, 980-989.
33. Moroni, G.; Trendelenburg, M.; del Papa, N.; Quaglini, S.; Raschi, E.; Panzeri, P.; Testoni, C.; Tincani, A.; Banfi, G.; Balestrieri, G.; et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am. J. Kidney Dis. 2001, 37, 490-498.
34. Siegert, C.E.; Daha, M.R.; Tseng, C.M.; Coremans, I.E.; van Es, L.A.; Breedveld, F.C. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann. Rheum. Dis. 1993, 52, 851-856.
35. Coremans, I.E.; Spronk, P.E.; Bootsma, H.; Daha, M.R.; van der Voort, E.A.; Kater, L.; Breedveld, F.C.; Kallenberg, C.G. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am. J. Kidney Dis. 1995, 26, 595-601.
36. Yap, D.Y.; Yung, S.; Zhang, Q.; Tang, C.; Chan, T.M. Mesangial cell-binding activity of serum immunoglobulin g in patients with lupus nephritis. PLoS ONE 2014, 9, e101987.
37. Manson, J.J.; Mills, K.; Jury, E.; Mason, L.; D’Cruz, D.P.; Ni, L.; Saleem, M.; Mathieson, P.; Isenberg, D.; Rahman, A. Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. Lupus Sci. Med. 2014, 1, e000013.
38. Rahman, A.; Isenberg, D.A. Systemic lupus erythematosus. N. Engl. J. Med. 2008, 358, 929-939.
39. Doria, A.; Gatto, M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus 2012, 21, 1492-1496.
40. Sekine, H.; Watanabe, H.; Gilkeson, G.S. Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J. Immunol. 2004, 172, 3913-3921.
41. Espeli, M.; Bokers, S.; Giannico, G.; Dickinson, H.A.; Bardsey, V.; Fogo, A.B.; Smith, K.G.C. Local renal autoantibody production in lupus nephritis. J. Am. Soc. Nephrol. 2011, 22, 296-305.
42. Ito, T.; Ishikawa, S.; Sato, T.; Akadegawa, K.; Yurino, H.; Kitabatake, M.; Hontsu, S.; Ezaki, T.; Kimura, H.; Matsushima, K. Defective B1 cell homing to the peritoneal cavity and preferential recruitment of B1 cells in the target organs in a murine model for systemic lupus erythematosus. J. Immunol. 2004, 172, 3628-3634.
43. Chan, O.T.; Hannum, L.G.; Haberman, A.M.; Madaio, M.P.; Shlomchik, M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 1999, 189, 1639-1648.
44. Chan, O.T.; Madaio, M.P.; Shlomchik, M.J. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J. Immunol. 1999, 163, 3592-3596.
45. Harris, D.P.; Haynes, L.; Sayles, P.C.; Duso, D.K.; Eaton, S.M.; Lepak, N.M.; Johnson, L.L.; Swain, S.L.; Lund, F.E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 2000, 1, 475-482.
46. Anolik, J.H.; Barnard, J.; Cappione, A.; Pugh-Bernard, A.E.; Felgar, R.E.; Looney, R.J.; Sanz, I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheumatol. 2004, 50, 3580-3590.
47. Dorner, T.; Jacobi, A.M.; Lee, J.; Lipsky, P.E. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J. Immunol. Methods 2011, 363, 187-197.
48. Tiller, T.; Tsuiji, M.; Yurasov, S.; Velinzon, K.; Nussenzweig, M.C.; Wardemann, H. Autoreactivity in human IgG+ memory B cells. Immunity 2007, 26, 205-213.
49. Odendahl, M.; Jacobi, A.; Hansen, A.; Feist, E.; Hiepe, F.; Burmester, G.R.; Lipsky, P.E.; Radbruch, A.; Dorner, T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 2000, 165, 5970-5979.
50. Jacobi, A.M.; Odendahl, M.; Reiter, K.; Bruns, A.; Burmester, G.R.; Radbruch, A.; Valet, G.; Lipsky, P.E.; Dorner, T. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2003, 48, 1332-1342.
51. Sun, C.Y.; Shen, Y.; Chen, X.W.; Yan, Y.C.; Wu, F.X.; Dai, M.; Li, T.; Yang, C.D. The characteristics and significance of locally infiltrating B cells in lupus nephritis and their association with local BAFF expression. Int. J. Rheumatol. 2013, 2013, 954292.
52. Renaudineau, Y.; Pers, J.O.; Bendaoud, B.; Jamin, C.; Youinou, P. Dysfunctional B cells in systemic lupus erythematosus. Autoimmun. Rev. 2004, 3, 516-523.
53. Wang, W.; Rangel-Moreno, J.; Owen, T.; Barnard, J.; Nevarez, S.; Ichikawa, H.T.; Anolik, J.H. Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche. J. Immunol. 2014, 192, 3011-3020.
54. Merrill, J.T.; Neuwelt, C.M.; Wallace, D.J.; Shanahan, J.C.; Latinis, K.M.; Oates, J.C.; Utset, T.O.; Gordon, C.; Isenberg, D.A.; Hsieh, H.J.; et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheumatol. 2010, 62, 222-233.
55. Rovin, B.H.; Furie, R.; Latinis, K.; Looney, R.J.; Fervenza, F.C.; Sanchez-Guerrero, J.; Maciuca, R.; Zhang, D.; Garg, J.P.; Brunetta, P.; et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheumatol. 2012, 64, 1215-1226.
56. Gunnarsson, I.; Jonsdottir, T. Rituximab treatment in lupus nephritis-Where do we stand? Lupus 2013, 22, 381-389.
57. Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D.J.; Tegzová, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J.T.; Chatham, W.W.; et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2011, 63, 3918-3930.
58. Navarra, S.V.; Guzman, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.; Thomas, M.; Kim, H.Y.; León, M.G.; et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377, 721-731.
59. Dooley, M.; Houssiau, F.; Aranow, C.; D’Cruz, D.P.; Askanase, A.; Roth, D.A.; Zhong, Z.J.; Cooper, S.; Freimuth, W.W.; Ginzler, E.M. et al. Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013, 22, 63-72.
60. D’Agati, V.D.; Appel, G.B.; Estes, D.; Knowles, D.M., 2nd; Pirani, C.L. Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int. 1986, 30, 573-581.
61. Mozes, E.; Lovchik, J.; Zinger, H.; Singer, D.S. MHC class I expression regulates susceptibility to spontaneous autoimmune disease in (NZBxNZW)F1 mice. Lupus 2005, 14, 308-314.
62. − double negative T cells and of the autoimmune syndrome in MRL-lpr/lpr mice. J. Autoimmun. 1995, 8, 33-45.
63. Adachi, Y.; Inaba, M.; Sugihara, A.; Koshiji, M.; Sugiura, K.; Amoh, Y.; Mori, S.; Kamiya, T.; Genba, H.; Ikehara, S. Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW × BXSB)F1 mice. Immunobiology 1998, 198, 451-464.
64. Masutani, K.; Akahoshi, M.; Tsuruya, K.; Tokumoto, M.; Ninomiya, T.; Kohsaka, T.; Fukuda, K.; Kanai, H.; Nakashima, H.; Otsuka, T.; et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheumatol. 2001, 44, 2097-2106.
65. Okamoto, A.; Fujio, K.; Tsuno, N.H.; Takahashi, K.; Yamamoto, K. Kidney-infiltrating CD4+ T-cell clones promote nephritis in lupus-prone mice. Kidney Int. 2012, 82, 969-979.
66. Tucci, M.; Lombardi, L.; Richards, H.B.; Dammacco F.; Silvestris, F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin. Exp. Immunol. 2008, 154, 247-254.
67. Akahoshi, M.; Nakashima, H.; Tanaka, Y.; Kohsaka, T.; Nagano, S.; Ohgami, E.; Arinobu, Y.; Yamaoka, K.; Niiro, H.; Shinozaki, M.; et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheumatol. 1999, 42, 1644-1648.
68. Masutani, K.; Taniguchi, M.; Nakashima, H.; Yotsueda, H.; Kudoh, Y.; Tsuruya, K.; Tokumoto, M.; Fukuda, K.; Kanai, H.; Hirakata, H.; Iida, M. Up-regulated interleukin-4 production by peripheral T-helper cells in idiopathic membranous nephropathy. Nephrol. Dial. Transplant. 2004, 19, 580-586.
69. Schwarting, A.; Wada, T.; Kinoshita, K.; Tesch, G.; Kelley, V.R. IFN-γ receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 1998, 161, 494-503.
70. Haas, C.; Ryffel, B.; Le Hir, M. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J. Immunol. 1997, 158, 5484-5491.
71. Kikawada, E.; Lenda, D.M.; Kelley, V.R. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-γ expression, and diminishes systemic pathology. J. Immunol. 2003, 170, 3915-3925.
72. Shimizu, S.; Sugiyama, N.; Masutani, K.; Sadanaga, A.; Miyazaki, Y.; Inoue, Y.; Akahoshi, M.; Katafuchi, R.; Hirakata, H.; Harada, M.; et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J. Immunol. 2005, 175, 7185-7192.
73. Fleming, S.D.; Monestier, M.; Tsokos, G.C. Accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. J. Immunol. 2004, 173, 4230-4235.
74. Zhang, Z.; Kyttaris, V.C.; Tsokos, G.C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009, 183, 3160-3169.
75. Kyttaris, V.C.; Zhang, Z.; Kuchroo, V.K.; Oukka, M.; Tsokos, G.C. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J. Immunol. 2010, 184, 4605-4609.
76. Kyttaris, V.C.; Kampagianni, O.; Tsokos, G.C. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed. Res. Int. 2013, 2013, 861028.
77. Crispin, J.C.; Oukka, M.; Bayliss, G.; Cohen, R.A.; van Beek, C.A.; Stillman, I.E.; Kyttaris, V.C.; Juang, Y.-T.; Tsokos, G.C. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 2008, 181, 8761-8766.
78. Dolff, S.; Quandt, D.; Wilde, B.; Feldkamp, T.; Hua, F.; Cai, X.; Specker, C.; Kribben, A.; Kallenberg, C.G.; Witzke, O. Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12, R150.
79. Chen, D.Y.; Chen, Y.M.; Wen, M.C.; Hsieh, T.Y.; Hung, W.T.; Lan, J.L. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012, 21, 1385-1396.
80. Zickert, A.; Amouddruz, P.; Sundstrom, Y.; Ronnelid, J.; Malmstrom, V.; Gunnarsson, I. Il-17 and IL-23 in lupus nephritis-Association to histopathology and response to treatment. BMC Immunol. 2015, 16, 7.
81. Schmidt, T.; Paust, H.J.; Krebs, C.F.; Turner, J.E.; Kaffke, A.; Bennstein, S.B.; Koyro, T.; Peters, A.; Velden, J.; Hünemörder, S.; et al. Function of the Th17/interleukin-17A immune response in murine lupus nephritis. Arthritis Rheumatol. 2015, 67, 475-487.
82. Kaplan, J.; Woodworth, L.; Smith, K.; Coco, J.; Vitsky, A.; McPherson, J. Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-β1 in the MRL/lpr lupus mouse model. Lupus 2008, 17, 822-831.
83. Xing, Q.; Su, H.; Cui J.; Wang, B. Role of Treg cells and TGF-β1 in patients with systemic lupus erythematosus: A possible relation with lupus nephritis. Immunol. Investig. 2012, 41, 15-27.
84. Xing, Q.; Wang, B.; Su, H.; Cui, J.; Li, J. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol. Int. 2012, 32, 949-958.
85. Feng, X.; Wang, D.; Chen, J.; Lu, L.; Hua, B.; Li, X.; Tsao, B.P.; Sun, L. Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. PLoS ONE 2012, 7, e51982.
86. Wong, C.K.; Wong, P.T.; Tam, L.S.; Li, E.K.; Chen, D.P.; Lam, C.W. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J. Clin. Immunol. 2010, 30, 45-52.
87. Chang, A.; Henderson, S.G.; Brandt, D.; Liu, N.; Guttikonda, R.; Hsieh, C.; Kaverina, N.; Utset, T.O.; Meehan, S.M.; Quigg, R.J.; et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 2011, 186, 1849-1860.
88. + T-cells in patients with active systemic lupus erythematosus. Exp. Biol. Med. (Maywood) 2013, 238, 193-199.
89. Yang, X.Y.; Wang, H.Y.; Zhao, X.Y.; Wang, L.J.; Lv, Q.H.; Wang, Q.Q. Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus. J. Clin. Immunol. 2013, 33, 767-774.
90. Leng, R.X.; Pan, H.F.; Ye, D.Q.; Xu, Y. Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am. J. Clin. Exp. Immunol. 2012, 1, 28-32.